We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Global Lateral Flow Assay Market Driven by Rising Incidence of Infectious Diseases

By LabMedica International staff writers
Posted on 19 Oct 2022

The global lateral flow assay market was valued at an estimated USD 7. More...

91 billion in 2021 and is expected to witness a CAGR of 5.23% during the forecast period 2021 to 2029, driven primarily by the increasing incidence of infectious diseases. Additionally, the rapid increase in geriatric population and rise in the use of home-based lateral flow assay devices will also fuel market growth. However, the lower accuracy of lateral flow assay tests and restricted compensation for lateral flow assay products are expected to restrain market growth.

These are the latest findings of Research and Markets (Dublin, Ireland), a provider of market research reports.

Based on application, the testing segment accounted for the highest share of the lateral flow assay market in 2021 and is expected to register the fastest growth during the forecast period, due to the adoption of point of care testing devices for qualitative and quantitative analysis worldwide. The drug development & quality testing segment is also anticipated to grow at a fast pace during the forecast period, due the launch of new testing techniques used for developing various drugs and quality checking. Based on product, the lateral flow readers segment held the highest share of the lateral flow assay market in 2021 and is expected to register the fastest growth during the forecast period. This can be attributed to lateral flow readers being extremely sensitive and their ability to enumerate and precisely capture and transmit data worldwide. The kits & reagents segment is also anticipated to grow at a fast pace during the forecast period, driven by increased initiatives by various public and private organizations to develop advanced lateral flow assay technologies.

Based on technique, the sandwich assays segment accounted for the highest share of the lateral flow assay market in 2021 and is expected to register the fastest growth during the forecast period due to the widespread applications of these assays for clinical testing across the world. The multiplex detection assays segment is also anticipated to grow at a fast pace during the forecast period, due to the advantages of these assays, such as high sensitivity and specificity for larger analysis. Based on sample type, the other samples segment held the highest share of the lateral flow assay market in 2021 and is expected to register the fastest growth during the forecast period due to a surge in R&D and the necessity for more specific and precise disease testing worldwide. The blood samples segment is also anticipated to grow at a fast pace during the forecast period, due to the number of tests that can be conducted by collecting blood samples and arriving at the correct diagnosis.

Geographically, North America accounted for the highest share of the global lateral flow assay market in 2021 and is expected to maintain its dominant position during the forecast period. Changes in various regulations, a growing geriatric population, increased government initiatives, and growing accessibility to technological advanced products are expected to fuel the growth of the North American lateral flow assay market. The lateral flow assay market in Asia Pacific is expected to register the fastest CAGR during the forecast period, owing to rising COVID 19 cases, increasing government and corporate investments in the healthcare sector, an aging population, and the availability of skilled labor at economic cost in the region.

Related Links:
Research and Markets 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.